ClinicalTrials.gg
CompletedNCT05795621Updated Feb 8, 2024

A Study of IBI311 in Subjects With Active Thyroid Eye Disease

A Phase 2/3 interventional study of IBI311 and placebo in Thyroid Eye Disease, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-08.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.

Enrollment
10th of 45
115 · median 64
Started
2023
with 5 others
Phase 2/3
3 of 55
none open now
Registered
19th of 55
by date
Lead sponsor
6 of 55
Innovent Biologics (Suzhou) Co. Ltd.

Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 10th largest by enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2023, is one of 3 in phase 2/3, and was the 19th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Graves Ophthalmopathy with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-masked, placebo-controlled Phase II/III study in subjects with active thyroid eye disease. Approximately 114 subjects meeting study eligibility criteria will be randomly assigned to IBI311 or placebo on day 1 (D1) in a 2:1 ratio stratified by smoking status

03

Conditions studied

  • Thyroid Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Written .
  2. Male or female subject between the ages of 18 and 80 years, inclusive, at Screening.
  3. Weight between 45 and 100 kg (inclusive).
  4. Clinical diagnosis of Graves' disease associated with active TED with a CAS ≥ 3 for at least one eye at Screening and Baseline.
  5. Moderate-severe active TED (not sight-threatening but has an appreciable impact on daily life), usually associated with at least two of the following: lid retraction ≥2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal for race and gender, and/or inconstant or constant diplopia.
  6. Female Subjects should be fertile women who are sterile or have a negative blood pregnancy test during the screening period and who agree to take measures within 120 days from the screening period to the last medication; Male subjects should agree to use contraception from the screening period to 120 days after the last dose.

Key Exclusion Criteria:

Subjects will be ineligible for study participation if they meet any of the following criteria:

  1. At the time of screening, according to the subject's chief complaint or medical record, the time of first symptoms of active thyroid eye disease appeared in > 270 days;
  2. Optimal corrected vision loss due to optic neuropathy, defined as two lines of vision loss due to optic neuropathy within the past 180 days, new visual field defects, or color vision impairment secondary to optic nerve involvement;
  3. Corneal ulcers with no relief after treatment were determined by the investigator;
  4. Baseline CAS decreased by more than 2 points compared with screening;
  5. At any time prior to baseline or during the study period planned to receive orbital radiation therapy or TED specific surgery, including orbital decompression, strabismus surgery, and eyelid retraction correction;
  6. Poor thyroid function control was defined as free triiodothyronine (FT3) or free tetriodothyronine (FT4) deviated more than 50% from the normal reference range of the local research center laboratory during screening;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
115 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants with TED will be randomized to receive 4 intravenous infusions of Placebo with an interval of 3 weeks for phase II and 8 intravenous infusions of Placebo with an interval of 3 weeks for phase III.

    Biological: IBI311 · Biological: placebo

  • Active comparator
    IBI311

    Participants with TED will be randomized to receive 4/8 intravenous infusions of IBI311 with an interval of 3 weeks for phase II/III.

    Biological: IBI311

Interventions

  • BiologicalIBI311

    10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.

  • Biologicalplacebo

    4 does of placebo for phase II; 8 does of placebo for phase III.

06

What researchers measure

Primary outcomes

  1. The proptosis responder rate of the study eye (defined as percentage of subjects with a ≥ 2mm reduction from Baseline in proptosis in the study eye, without deterioration [≥ 2 mm increase] of proptosis in the non-study eye).

    proptosis assessment: amount of protrusion of the eye from the orbital rim measured by Hertel exophthalmometer

    Time frame: Week 12 for phase II, Week 24 for phase III

Secondary outcomes

  1. The overall responder rate in the study eye.

    Responder rate were defined as participants with a reduction in clinical activity score (CAS, see Secondary Outcome Measure 2 description for details) of ≥ 2 points, and a reduction in proptosis of ≥ 2 mm in the study eye, and no deterioration (increase in CAS of ≥ 2 points or increase in proptosis of ≥ 2 mm) in the non-study eye.)

    Time frame: Week12 and Week24 for phase II, Week 24 for phase III

  2. Percentage of subjects with a CAS value of 0 or 1 in the study eye.

    According to the 7-item European Group on Graves' Ophthalmopathy (EUGOGO) amendment, CAS was used to evaluate clinical activity. For each of the following items, one point is given: spontaneous orbital pain, gaze evoked orbital pain, eyelid swelling that is considered to be due to active (inflammatory phase) Graves' ophthalmopathy (GO), eyelid erythema, conjunctival redness that is considered to be due to active (inflammatory phase) GO, chemosis, and inflammation of caruncle or plica. The sum of these points is the total score, with 0 indicating no clinical activity and 7 indicating the most severe clinical activity.

    Time frame: Week12 and Week24 for phase II, Week 24 for phase III

  3. Mean Change of the CAS value in the study eye.

    Time frame: Baseline to Week 12 and Week 24 for phase II

  4. Mean change from Baseline in proptosis measurement in the study eye.

    proptosis measurement: see Primary Outcome Measure 1 description for details

    Time frame: Baseline to Week 12 and Week 24 for phase II, Baseline to Week 24 for phase III

  5. The proptosis responder rate of the study eye.

    proptosis responder rate: see Primary Outcome Measure 1 description for details

    Time frame: Week 24 for phase II

  6. The diplopia responder rate of the study eye.

    Time frame: Week12 and Week24 for phase II, Week 24 for phase III

07

Study locations

1 site
  • Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
    Shanghai, Shanghai 200000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Dec 2023, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Apr 3, 2023
StartActual
Feb 14, 2023
Primary completionActual
Dec 20, 2023
CompletionActual
Dec 20, 2023
Last update
Feb 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05795621
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Feb 14, 2023
Primary completion
Dec 20, 2023
Completion
Dec 20, 2023
Last update
Feb 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI311

Start the discussion